Patients with inflammatory bowel disease treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results.

Franck Carbonnel, MD, of the department of gastroenterology at Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, and colleagues wrote that despite their efficacy in patients with IBD, anti-TNF agents come with risks, as do thiopurines.

“These medications have potential serious adverse effects such as infections and malignancy,” they wrote. “Lymphoma has been shown to

Full Article: https://www.healio.com/news/gastroenterology/20200826/antitnf-thiopurine-combination-increase-lymphoma-risk-in-ibd